men with advanced prostate cancer could benefit from a pioneering drug originally meant for women . olaparib is the first cancer drug to target inherited genetic mutations . cancer cells that have a mutation in a brca gene rely completely on the parp protein to fix the damage . professor johann de bono , who was the trial chief investigator , said : ‘ this opens up the exciting possibility of delivering precise treatment for advanced prostate cancer , guided by genomic testing and based on the molecular characteristics of patients’ tumours . '